Ranting in 2025: It’s Not the Same Rant

Alder S . What is the physician’s payments sunshine act? HIPPA Journal, October 22, 2024. Available from: https://www.hipaajournal.com/physician-payments-sunshine-act/ [Last accessed: December 24, 2024 ].

Physician financial transparency reports (Sunshine Act). American Medical Association. Available from: https://www.ama-assn.org/practice-management/medicare-medicaid/physician-financial-transparency-reports-sunshine-act?linkid=popularlinksbox-1 [Last accessed: December 26, 2024 ].

U.S. Department of Health and Human Services Centers for Medicare and Medicaid Services. Report to Congress. Fiscal Year 2023, Annual Report on the Open Payment Program, 2024. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.cms.gov/files/document/open-payments-fy-2023-report-congress.pdf

US Department of Justice. Medtronic to pay over $9.2 million to settle allegations of improper payments to South Dakota neurosurgeon. October 29, 2020. Available from: https://www.justice.gov/opa/pr/medtronic-pay-over-92-million-settle-allegations-improper-payments-south-dakota-neurosurgeon. [Last accessed: December 24, 2024 ].

Nguyen D-D , Muramaya A , Nguyen A-L , et al. Payment by drug and medical device manufacturers to US peer-reviewers of major medical journals. JAMA, 2024; 332(17):1480–1482; doi: 10.1001/jama.2024.17681

Murphy B , Mierjeski A . Clarence Thomas’ 38 vacations: The other billionaires who have treated the supreme court justice to luxury travel. Propublica.org, August 10, 2023, The Other Billionaires Who Helped Clarence Thomas Live a Luxe Life—ProPublica. 2024. accessed December 24, 2024.

Savage C . Judge Thomas did not disclose additional trips, Democrats say. New York Times Dec 21, 2024 Justice Clarence Thomas Did Not Disclose Additional Trips From Billionaire Patron, Democrats Say—The New York Times accessed December 24, 2024.

Gonsalves-Brown S . Congressional stock trading continues to raise conflicts of interest. Available from: Campaignlegal.org September 5, 2024, Congressional Stock Trading Continues to Raise Conflicts of Interest Concerns, Campaign Legal Center [Last accessed: December 24, 2024 ].

Karaahmetovic V . These Congress members made the highest stock returns in 2023. Finbold, January 3, 2024. These Congress members made the highest stock returns in 2023. [December 24, 2024].

Axelrod DR , Welsh HL . Politician trading: If you can’t stop them, join them. Available from: Law.com October 2, 2024. Politician Trading: If You Can’t Stop Them, Join Them | Alerts and Articles | Insights | Ballard Spahr [Last accessed: December 24, 2024 ].

The Lewin Group. Endocrine Workforce: Supply and Demand Projections. Washington DC: Endocrine Society; 2014. 2014-06-white-paper–endocrinology-workforce.pdf [December 24, 2024].

2023-MPSM-Match-Results-Statistics-Report.pdf [December 25, 2024].

Healy AM , Tanenberg RJ , Schwartz FL , Shubrook JH . Diabetes fellowship in primary care: A survey of graduates. J Am Osteopath Assoc, 2018; 118(8):538–543.

American College of Diabetology. 2024 [December 25, 2024].

Endocrinologist Demographics and Statistics. Number Of Endocrinologists In The US., 2024. [December 25, 2024].

Tonnies T , Brinks R , Isom S , et al. Populations of type 1 and type 2 diabetes burden in the US population aged <20 years thorough 2060: The SEARCH for diabetes in youth study. Diabetes Care, 2023; 46(2):313–320.

How Much Do Doctors Make? [Salary by Specialty 2024]. White Coat Investor [December 25, 2024].

Teupe B , Bergis K . Epidemiological evidence for “double diabetes. Lancet, 1991; 337(8737):361–362.

Garg SK , Kaur G , Haider Z , et al. Efficacy of semaglutide in overweight and obese patients with type 1 diabetes. Diabetes Technol Ther, 2024; 26(3):184–189.

Akturk HK , Dong F , Snell-Bergeon JK , et al. Efficacy and safety of tirzepatide in adults with type 1 diabetes. A proof of concept observational study. J Diabetes Sci Technol, 2024; 5:19322968231223991.

Snell-Bergeon J , Kaur G , Renner D , et al. Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes. Diabetes Technol Ther, 2025; 27(1):1–9; doi: 10.1089/dia.2024.0328

Garg SK , Kaur G , Renner D , et al. Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther, 2025; 26(6):367–374.

Trial of semaglutide for diabetic kidney disease in type 1 diabetes. NCT05822609. 2024.

Hirsch IB , Schatz DA . The impact of the US election on diabetes. Lancet Diabetes Endocrinol, 2025; 13(1):8–9.